Hansa Biopharma Unveils Promising Five-Year Follow-Up Data for Imlifidase in Kidney Transplantation at ESOT Congress 2025
London, UK – June 30, 2025 – Hansa Biopharma, a pioneer in enzyme technology for rare immunological diseases, today announced the presentation of compelling positive outcomes from a five-year follow-up study of its investigational therapy, imlifidase, in kidney transplantation. The findings were shared with the global medical community at the esteemed European Society for Organ Transplantation (ESOT) Congress 2025, held in London.
This significant milestone study provides crucial long-term data on the efficacy and safety of imlifidase, an enzyme designed to cleave IgG antibodies, in the context of kidney transplantation. The research focuses on its potential to enable transplantation for highly sensitized patients who have developed antibodies against human leukocyte antigens (HLA), a common barrier to successful organ donation.
The presented results are particularly encouraging, demonstrating sustained benefits and a manageable safety profile over a five-year period. While specific details of the outcomes are being shared at the congress, the overall sentiment from Hansa Biopharma indicates a strong potential for imlifidase to dramatically improve the prospects for individuals awaiting kidney transplants, who often face prolonged waiting lists and limited viable donor options due to antibody-mediated rejection.
Imlifidase has garnered attention for its novel mechanism of action, which aims to temporarily reduce the levels of pre-formed anti-HLA antibodies. This reduction can create a critical window of opportunity for transplanting a kidney from a living or deceased donor, even in the presence of sensitization. The extended follow-up data is vital in understanding the long-term impact of this approach on graft survival and patient outcomes.
The presentation at ESOT Congress 2025, a leading international forum for transplant professionals, underscores Hansa Biopharma’s commitment to advancing the field of transplantation and addressing unmet medical needs. The opportunity to share these five-year follow-up results with leading experts in organ transplantation is expected to generate significant interest and further validate the potential of imlifidase.
Hansa Biopharma continues to be dedicated to the development of innovative therapies that can transform the lives of patients with rare and serious conditions. The positive outcomes from this long-term study represent a significant step forward in their mission to offer new hope to kidney transplant candidates worldwide. Further details regarding the study’s specific endpoints and conclusions are anticipated to be made available following the presentation at the congress.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
www.prnewswire.com published ‘Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London’ at 2025-06-30 06:15. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.